DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ... New England Journal of Medicine 355 (10), 983-991, 2006 | 2348 | 2006 |
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ... Clinical Cancer Research 17 (18), 6012-6020, 2011 | 786 | 2011 |
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma AS Berghoff, B Kiesel, G Widhalm, O Rajky, G Ricken, A Wöhrer, ... Neuro-oncology 17 (8), 1064-1075, 2015 | 603 | 2015 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal … M Gnant, M Filipits, R Greil, H Stoeger, M Rudas, Z Bago-Horvath, ... Annals of oncology 25 (2), 339-345, 2014 | 457 | 2014 |
ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 432 | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients P Dubsky, JC Brase, R Jakesz, M Rudas, CF Singer, R Greil, O Dietze, ... British journal of cancer 109 (12), 2959-2964, 2013 | 383 | 2013 |
Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung … FA Shepherd, C Domerg, P Hainaut, PA Jänne, JP Pignon, S Graziano, ... Journal of clinical oncology 31 (17), 2173-2181, 2013 | 370 | 2013 |
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ... Journal of Thoracic Oncology 5 (10), 1706-1713, 2010 | 358 | 2010 |
EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases K Schmid, N Oehl, F Wrba, R Pirker, C Pirker, M Filipits Clinical Cancer Research 15 (14), 4554-4560, 2009 | 344 | 2009 |
Prognostic effect of tumor lymphocytic infiltration in resectable non–small-cell lung cancer E Brambilla, G Le Teuff, S Marguet, S Lantuejoul, A Dunant, S Graziano, ... Journal of clinical oncology 34 (11), 1223-1230, 2016 | 334 | 2016 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and … I Sestak, J Cuzick, M Dowsett, E Lopez-Knowles, M Filipits, P Dubsky, ... Journal of clinical oncology 33 (8), 916-922, 2015 | 270 | 2015 |
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer M Filipits, TO Nielsen, M Rudas, R Greil, H Stöger, R Jakesz, ... Clinical Cancer Research 20 (5), 1298-1305, 2014 | 269 | 2014 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer P Dubsky, M Filipits, R Jakesz, M Rudas, CF Singer, R Greil, O Dietze, ... Annals of oncology 24 (3), 640-647, 2013 | 237 | 2013 |
Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis C Perisanidis, A Psyrri, EE Cohen, J Engelmann, G Heinze, B Perisanidis, ... Cancer treatment reviews 41 (10), 960-970, 2015 | 170 | 2015 |
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non–small cell lung carcinoma J Voortman, A Goto, J Mendiboure, JJ Sohn, AJ Schetter, M Saito, ... Cancer research 70 (21), 8288-8298, 2010 | 170 | 2010 |
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group M Filipits, G Pohl, M Rudas, O Dietze, S Lax, R Grill, R Pirker, CC Zielinski, ... Journal of clinical oncology 23 (6), 1161-1168, 2005 | 166 | 2005 |
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement HA Azim Jr, S Michiels, F Zagouri, S Delaloge, M Filipits, M Namer, ... Annals of oncology 24 (3), 647-654, 2013 | 163 | 2013 |
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8 MP Goetz, VJ Suman, TL Hoskin, M Gnant, M Filipits, SL Safgren, M Kuffel, ... Clinical Cancer Research 19 (2), 500-507, 2013 | 153 | 2013 |
Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia M Filipits, G Pohl, T Stranzl, RW Suchomel, RJ Scheper, U Jäger, ... Blood, The Journal of the American Society of Hematology 91 (5), 1508-1513, 1998 | 151 | 1998 |
MRP and MDR1 gene expression in primary breast carcinomas. M Filipits, RW Suchomel, G Dekan, K Haider, G Valdimarsson, D Depisch, ... Clinical cancer research: an official journal of the American Association …, 1996 | 149 | 1996 |